Importance of Postoperative Stimulated Thyroglobulin Level at the Time of 131I Ablation Therapy for Differentiated Thyroid Cancer |
Hasbek, Zekiye
(Nuclear Medicine, Medicine School, Cumhuriyet University)
Turgut, Bulent (Nuclear Medicine, Medicine School, Cumhuriyet University) Kilicli, Fatih (Department Endocrinology, Medicine School, Cumhuriyet University) Altuntas, Emine Elif (Department Ear Noise and Thourat, Medicine School, Cumhuriyet University) Yucel, Birsen (Department Radiation Oncology, Medicine School, Cumhuriyet University) |
1 | Francis Z, Schlumberger M (2008). Serum thyroglobulin determination in thyroid cancer patients. Best Pract Res Clin Endocrinol Metab, 22, 1039-46. DOI ScienceOn |
2 | Frasoldati A, Pesenti M, Gallo M, et al (2003). Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer, 97, 90-6. DOI ScienceOn |
3 | Ibrahimpasic T, Nixon IJ, Palmer FL, et al (2012). Undetectable thyroglobulin after total thyroidectomy in patients with lowand intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy? Surgery, 152, 1096-105. DOI ScienceOn |
4 | Kucukalic-Selimovic E, Alagic J, Valjevac A, et al (2012). The value of serum thyreoglobulin levels and whole body (I-131) scintigraphy in the follow-up of the thyroid cancer patients after thyroidectomy. Coll Antropol, 2, 67-71. |
5 | Pacini F, Capezzone M, Elisei R, et al (2002). Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab, 87, 1499-501. DOI |
6 | Tuttle RM, Tala H, Shah J, et al (2010). Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid, 20, 1341-9. DOI ScienceOn |
7 | Ito Y, Kudo T, Kihara M, et al (2012). Prognosis of low-risk papillary thyroid carcinoma patients: its relationship with the size of primary tumors. Endocr J, 59, 119-25. DOI ScienceOn |
8 | Kim TY, Kim WB, Kim ES, et al (2005). Serum thyroglobulin levels at the time of remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab, 90, 1440-5. DOI |
9 | Koh JM, Kim ES, Ryu JS, et al (2003). Effects of therapeutic doses of in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131-I whole-body scan: comparative study. Clin Endocrinol, 58, 421-7. DOI ScienceOn |
10 | Lee JI, Chung YJ, Cho BY, et al (2013). Postoperative-stimulated serum thyroglobulin measured at the time of 131-I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma. Surgery, 153, 828-35. DOI ScienceOn |
11 | Baudin E, Cao CD, Cailleux AF, et al (2003). Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab, 88, 1107-11. DOI ScienceOn |
12 | Leenhardt L, Erdogan MF, Hegedus L, et al (2013). Europan Thyroid Association Guidelines for cervical ultrasound scan and ultrasound-guide techniques in the postoperative mangement of patients with thyroid cancer. Eur Thyroid J, 2, 147-59. DOI ScienceOn |
13 | Nascimento C, Borget I, Al Ghuzlan A, et al (2011). Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer, 18, 29-40. |
14 | Cooper DS, Doherty GM, Haugen BR, et al (2009). Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 91, 1167-214. |
15 | Berger F, Friedrich U, Knesewitsch P, Hahn K (2011). Diagnostic whole-body scintigraphy 1 year after thyroablative therapy in patients with differentiated thyroid cancer: correlation of results to the individual risk profile and longterm follow-up. Eur J Nucl Med Mol Imaging, 38, 451-8. DOI |
16 | Castagna MG, Maino F, Cipri C, et al (2011). Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol, 165, 441-6. DOI ScienceOn |
17 | Durante C, Costante G, Filetti S (2013). Differentiated thyroid carcinoma: defining new paradigms for postoperative management. Endocr Relat Cancer, 20, 141-54. DOI ScienceOn |